Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599098 | 1.00 | NR4A1 (0.59) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL32665708 | 0.86 | NR4A1 (0.61) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL5716814 | 0.86 | NR4A1 (0.61) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL4828437 | 0.85 | NR4A1 (0.55) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL1164084 | 0.83 | NR4A1 (0.63) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL25057402 | 0.82 | NR4A1 (0.57) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL4099062 | 0.82 | NR4A1 (0.57) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL10358074 | 0.82 | NR4A1 (0.57) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL6008119 | 0.82 | NR4A1 (0.57) | NR4A1NR4A2NR4A3PLK1MMP3 | |
| SCHEMBL5125965 | 0.82 | NR4A1 (0.57) | NR4A1NR4A2NR4A3PLK1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527823-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2571859-B1 | 1-PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RES TRIANGLE INST (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE | 2015-05-21 | — | — | US | disclosed |
| US-8906908-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2571859-A2 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146821-A2 | 1 - PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1474140-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003068226-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-4891431-A | REMOVAL OF BY-PRODUCT FORMIC ACID | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0252162-A1 | PROCESS FOR PREPARING 2-UNSUBSTITUTED IMIDAZOLES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | NR4A1 360/4885NR4A2 414/4885NR4A3 288/4885 |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | NR4A1 360/4885NR4A2 414/4885NR4A3 288/4885 |
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | NR4A1 379/4885NR4A2 485/4885NR4A3 434/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | NR4A1 121/4885NR4A2 205/4885NR4A3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.